Nustendi (Ezetimibe, Bempedoic Acid)

Ezetimibe, the active ingredient in Nustendi, is a combination lipid‑lowering agent presented as a tablet for oral use. It lowers cholesterol and triglyceride levels in adults with primary hyperlipidemia, particularly when diet and statin therapy alone are insufficient. GNH USA supplies Nustendi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nustendi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nustendi is indicated for disorders of lipid metabolism that require additional cholesterol reduction beyond statin therapy.

- Primary hyperlipidemia: provides additional lowering of LDL‑cholesterol when statins alone are inadequate. - Heterozygous familial hypercholesterolemia: helps achieve target LDL‑cholesterol levels in patients with this genetic condition. - Secondary prevention of cardiovascular disease: reduces LDL‑cholesterol as part of a comprehensive risk‑reduction strategy after myocardial infarction or stroke.

Adverse reactions reported with the ezetimibe/bempedoic acid combination are generally mild to moderate.

Common Side Effects: - Headache: mild, transient headache. - Muscle pain: occasional myalgia without significant CK elevation. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Elevated liver enzymes: mild, reversible increases in ALT/AST. - Fatigue: general tiredness reported by some patients.

Serious or Rare Side Effects: - Rhabdomyolysis: rare severe muscle breakdown, especially with concurrent statins. - Severe liver injury: uncommon but may present with jaundice or marked enzyme rise. - Allergic reactions: rash, pruritus, or angio‑edema in hypersensitive individuals. - Acute kidney injury: rare cases of renal function decline. - Tendon rupture: isolated reports in patients on concomitant statin therapy.

When prescribing Nustendi, clinicians should consider several safety aspects.

- Liver function monitoring: check ALT/AST before initiating therapy and periodically thereafter. - Statin co‑administration: assess risk of myopathy when used with high‑intensity statins. - Renal impairment: use caution in patients with severe kidney disease. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Drug interactions: review concomitant medications for potential CYP or transporter effects. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Nustendi may interact with several drug classes; interactions are categorized by clinical relevance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may reduce bempedoic‑acid exposure. - High‑intensity statins (e.g., rosuvastatin >20 mg): increase risk of myopathy.

Moderate Interactions (Monitor Closely): - Bile‑acid sequestrants: may lower ezetimibe absorption; separate dosing by at least 2 h. - Fibrates: additive risk of liver enzyme elevation. - Anticoagulants (warfarin): potential alteration of INR; monitor coagulation parameters. - Antidiabetic agents: monitor glucose control as lipid‑lowering may affect glycaemia.